Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

The Oncology Nurse Advisor Summit spotlights CAR T-cell therapy, bispecific antibodies, and immunotherapy nursing best practices.

Immune checkpoint inhibitors (ICIs) are a form of immunotherapy that activates anti-tumor immune cells. In the context of ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing ...

After months of shrinking scans, the tumors suddenly came roaring back. Oncologists have seen this pattern for years in ...

Researchers have discovered that activating the pentose phosphate pathway makes antitumor CD8+ T cells more likely to stay in an immature, stem-like, “precursor” state. Combining this metabolic ...

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. A recent study reviews recent developments in ...

Clinical and genetic risk factors can help identify individuals at risk for immune checkpoint inhibitor-induced diabetes, according to results of a cohort study. Researchers at an academic integrated ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. Checkpoint ...

Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger patients and those with a history ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. Studies included in the review were mostly ...